The life-science incubator in Geneva

The life-science incubator in Geneva

The life-science incubator in Geneva

24

Companies since 2004

118

Collaborators in the Eclosion environment

300

Millions CHF of capital raised by portfolio companies

1

IPO in April 2016

Molecular

Mission

The Foundation Eclosion mission is to foster entrepreneurs in translating their life science innovation into economic value and jobs in the Geneva’s region.

Offer

We provide entrepreneurs with the key resources required to bridge the gap from laboratory to start-up:

  • LABORATORY AND OFFICE INFRASTRUCTURE
  • BUSINESS AND SCIENTIFIC SUPPORT
  • FINANCIAL SUPPORT
  • OTHER SERVICES

Offer

We provide entrepreneurs and scientists with the key ressources to cross the bridge frpom laboratory to the start-up:

  • Infrastructure
  • Business and scientific support
  • Funding
  • Other services
Infrastructure

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilising more than 800 sq m of laboratories located at the (CTN – Centre des Technologies Nouvelles) and 500 sq m of offices at both the CTN and Campus Biotech Innovation Park (CBIP).

Laboratory and office infrastructure

Eclosion incubates projects and hosts start-up companies utilizing more than 800 sq m of laboratories located at the (CTN – Centre des Technologies Nouvelles) and 500 sq m of offices at both the CTN and the Campus Biotech Innovation Park (CBIP).

Infrastructure

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Business and scientific support

Eclosion provides the support to entrepreneurs from seasoned life science and finance professionals, including its Advisory Board, to assist in the design and implementation of development plans, as well as best positioning companies towards the market.

Business & Scientific Support

Financial Support

Eclosion services include financial support to conduct key experiments and access to the finance community to seed and fund start-up companies.

Financial Support

Eclosion services include; financial support to conduct key experiments and access to the finance community to seed and fund start-up companies.

Other services

Eclosion also provides a wide range of additional services, including administration, accounting and payroll support.

Other Services

Other services

Eclosion also provides a wide range of additional services, including administration, accounting and payroll support, as well as access to business intelligence databases.

Other Services

Community

Eclosion is fully integrated in the vibrant life-science community of Geneva and Switzerland, including economic promotion agencies, investors, research institutes, and the Swiss Commission for Technology and Innovation.

Portfolio

Their success is our success:

Product companies at various stages of development, addressing high-unmet medical needs in various therapeutic areas including oncology, neurology, gastroenterology, rare diseases and cardiovascular diseases.

Service companies including proprietary technology and life science consulting.

Leadership

The team

Christophe Guichard

Christophe is dedicating his energy and passion to life-science start-up companies as Director of Eclosion since 2008. He is also contributing his experience in managing finance and legal activities and served as CFO for companies including GeNeuro, GenKyoTex and DepGen, raising over CHF 150m in equity. Prior to joining Eclosion, he held various corporate finance positions including CFO of a European listed company and manager with KPMG-Salustro, building organizations and performing M&A transactions and two IPOs. Christophe is a graduate from EDHEC Business School and from Harvard Business School. He also holds a postgraduate degree in Finance and Accounting (DESCF).

Yann Dean

Yann Dean holds a PhD from the University Of Wales College Of Medicine, Cardiff, UK. He has 15 years of experience in the biotech sector. Before joining Eclosion, Yann worked at NovImmune SA, where he developed one therapeutic monoclonal antibody from research to clinical phase IIa as Project Leader and participated in the development (from bench to bedside) of five other monoclonal antibodies as Preclinical Manager. Yann has published several peer-reviewed scientific articles and authored multiple patents related to the validation of therapeutic targets and development of biological drugs.

Farid Bouzidi

Farid joined Eclosion as Scientific Director. Farid has more than 15 years’ experience in Business/Corporate/Product Development across a range of clinical indications including CNS, autoimmune diseases, oncology, and infectious diseases. With his experience at Institut Pasteur, he has a strong emphasis on entrepreneurship, value creation and incubation. He has worked in many organisations including Genentech, Roche, AC Immune and as an independent consultant covering projects from discovery to clinical development and marketed products. Farid is currently a senior advisor to the Institut Pasteur for innovative projects. Farid obtained his Ph.D. in Biophysics and Biochemistry from CEA and MBA from EM-Lyon, France.

Operational and Scientific Management

Yann Dean holds a PhD from the University Of Wales College Of Medicine, Cardiff, UK. He has 15 years of experience in the biotech sector. Before joining Eclosion, Yann worked at NovImmune SA, where he developed one therapeutic monoclonal antibody from research to clinical phase IIa as Project Leader and participated in the development (from bench to bedside) of five other monoclonal antibodies as Preclinical Manager. Yann has published several peer-reviewed scientific articles and authored multiple patents related to the validation of therapeutic targets and development of biological drugs.

Marlène Bon holds a Higher Diploma in Accounting and Management. Having practiced as an Accountant she joined a local SME (Small and Medium Enterprise) and took part in its development in the role of Administrator (Accounting and Human Relations). She became Office Manager of Eclosion in June, 2014.

Foundation Council

Jean-Dominique Vassalli, former Rector of the University of Geneva, is a Swiss scientist and physician. After obtaining a Swiss Federal Diploma of Medicine at the University of Geneva in 1972, he earned a PhD degree from The Rockefeller University, New York, in 1977 and a Doctorate in Medicine from the University of Geneva in 1984. In 1986, he became professor of developmental biology in the Faculty of Medicine. His laboratory was involved in studies on extracellular proteolysis in mammalian embryogenesis, inflammation and neuronal function, and on translational control of gene expression in gametogenesis. From 1991 to 1999, he was Vice-Dean of the Faculty of medicine, then Vice-Rector of the University of Geneva until 2003. From 2003 to 2007 he was President of Basic Medical Sciences in the Faculty of Medicine. He was appointed Rector of the University of Geneva in 2007, and ended his second term in 2015. He is a recipient of the Cloëtta Prize (1988), of the International Society for Fibrinolysis and Thrombolysis Prize (1994) and an ad personam member of the Swiss Academy of Medical Sciences (2001). Since 2011, he is president of the Brocher Foundation, which encourages multidisciplinary research in the ethical, legal and social implications of the development of medical research and biotechnologies. Jean-Dominique is Professor emeritus of the Faculty of Medicine.

Robin Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Robin serves as a board member and is Chairman of the Advisory Board of Eclosion

Emanuela Dose-Sarfatis qualified as an attorney. She managed the legal department of a private bank in Lausanne and was a member of her local council before joining Geneva cantonal council in 1994. Emanuela is a member of the directorate general for economic affairs within the department of regional, economic and health affairs, delegated by the cantonal counsel to the boards of the Fondation d’Aide aux Entreprises, the Coopérative Romande de Cautionnement en Faveur des PME, the Fondation Genevoise pour l’Innovation Technologique, and Eclosion SA. She also advises the Conseil de Surveillance du Marché de l’Emploi, the Commission Tripartite Préavisant les Demandes d’Autorisations de Travail, the Conseil Interprofessionnel pour la Formation, and the Conseil de Fondation de l’Ecole Internationale de Genève.

Monica Malcarne is currently the Site Lead for Covance Central Laboratory and Director of Sample & Archive Services, servicing all clinical trials for Central and Early Development laboratories based in the US and in Europe. Her responsibilities included Laboratory Pre/Post-Analytical Sample Management, BioRepository Services and Archive Services. She joined SciCor (now Covance) in 1995 as Investigator Services Administrator before moving to a Project Manager role, executing Study Design, Coordination and Management for key accounts.  In 2002 she moved into leadership roles starting with Team Manager in Geneva and Indianapolis where she relocated in 2004. In 2006 she ensured the General Management of our operations in Shanghai, China and then in Zeist, the Netherlands were she transferred until end of 2007. Relocating in Geneva in 2008 she accepted the role of Director of Global Laboratory Support Services before taking the role of Director of Global Sample Services. As the Site Lead of the Geneva site, Monica enabled opportunities and initiatives in a sustainable way while cultivating an inclusive approach, such as events for the employees by the employees in the sport, health and wellness areas, corporate social responsibility and communication. Monica holds a Master of Art degree in Social and Political Sciences from Lausanne University, Switzerland.

François Conquet defended his PhD in 1991, at the Pasteur Institute in Paris, in the lab of François Jacob. Then, he did his Post-doc at Genentech in the US. After that, he joined the GSK Research Institute of Geneva where he worked as a scientist in CNS research until 2001. His main field of interest was to validate metabotropic Glutamate receptors for CNS diseases. Then, he left GSK to found Addex Pharmaceuticals in Geneva, where he stayed CEO until 2005. Addex is a Biotech company dedicated to the discovery of novel treatments for CNS diseases and particularly focused on the development of mGluR5 antagonists. In 2005, he worked as an acting CEO for a VC firm in three different French Biotechs, before joining Merck Serono in September 2006 as Director, Early Stage Licensing, where he managed the in-licensing of several novel preclinical programs. François is the author of more than 40 peer reviewed scientific articles and inventor in 2 patents.

Antoine Geissbuhler is a Professor of Medicine, Chairman of the Department of Radiology and Medical Informatics at Geneva University, Director of the Division of eHealth and Telemedicine at Geneva University Hospitals. He is also President of the Health-On-the-Net Foundation, Past-President of the International Medical Informatics Association, and Fellow of the American College of Medical Informaticians. His research focuses on the development of innovative, knowledge-enabled information systems and computer-based tools for improving the quality, safety and efficiency of care processes, and on the evaluation of their impact on health outcomes, at the local level of the largest hospital in Switzerland, in the regional patient-centered health information system, at the global level with the Health-On-the-Net Foundation, as director of the WHO collaborating center for eHealth, and as director of the RAFT network, an extensive South-South telemedicine network linking hundreds of hospitals in 20+ developing countries (http://raft.network).

Jean-Marc Leroux is Chief Innovation Officer for the Covance Drug Development business of LabCorp, General Manager CCLS Europe from November 2015. Throughout Jean-Marc’s 17 years career with Covance, he has been instrumental in shaping the Central Laboratory strategy, and securing new talent and technology to deliver strategic advances in that business.  He progressed through various leadership positions in Central Laboratories, including Vice President of Global Laboratory Operations (managing more than 1’000 HC globally) and Scientific/ Technical Affairs, Vice President for all Central Laboratory Global Operations (Laboratory, Sample Management/Lab Pre-analytical Services, Investigator Site Support, Logistics, and Kit Production), and most recently Vice President of Global Innovation & GM Europe for CLS.  He has always been dedicated to identifying new technology and business innovations throughout his career at Covance, advocating for state of the art Laboratory automation, advances in informatics, and new services like biomarkers and point of care devices. Visioning with the ability to evaluate, drive and close strategic partnership and M&A.Prior to joining Covance, Jean Marc Leroux launched his own network of diagnostics labs in France, implemented the central laboratory division for clinical trials at Pasteur Institute and worked in different European CROs and Board Member (Eclosion, Metaphora). Headed by Jean-Marc Leroux the Geneva site has earned a string of awards for car sharing, reducing biohazard waste, 1st Prize of Economy in 2014 and recognized as the largest automated Central Lab for Clinical Trials in Europe.

Ernest holds MD, PhD degrees, with a specialization in Obstetrics and Gynaecology from Louvain University, Belgium. He was a research fellow at the National Institute of Child Health and Human Development in the US and is the author of over 90 publications in peer-reviewed journals. After a brief academic career at Louvain University Hospital, he joined Serono as Head of Clinical Development for Reproductive Health (Geneva and Boston). He contributed actively to the worldwide registration of three important biotechnology products. In 2003, Ernest joined Ipsen in Paris as Vice President, Medical Sciences. In 2006, Ernest co-founded PregLem, a Swiss based specialty biopharmaceutical company. As CEO, he led the company up to the successful European registration of Esmya®, its lead product. The company was acquired by Gedeon Richter Plc. in 2010.

In 2012, Ernest co-founded ObsEva and since then has served as the CEO of the company. Ernest was a visiting Professor of Reproductive Endocrinology at Louvain University, Brussels from 2002 to 2010, where he held a full time clinical and academic position until 1991.

François Naef joined Waypoint as Group General Counsel and a Member of the Board of Directors in 2014. His responsibility also includes Waypoint’s Human Resources. Prior to joining, François was Group General Counsel, Head of Legal, Compliance and Internal Auditing of Merck as well as the Chairman of their Swiss board.

François joined Merck following its acquisition of Serono in 2007 and was Chief Administration Officer and Head of Human Resources, Legal and Communications of Merck Serono from 2007 until 2009. Previously he was General Manager of Serono International S.A, the Geneva based operations of Serono, having held many positions in the company since joining in 1988, including as head of HR, Legal and Communications.

Before Serono, François Naef was an attorney in Geneva. He was the Chairman of the Geneva Chamber of Commerce from 2008 to 2012.

Julien Storaï has done all his carrier in Biotech and Pharma Manufacturing. He holds an MSc of Biochemistry Engineer combined with an MSc of Industrial Microbiology. Between 2004 and 2007 he gained a PhD in Industrial Microbiology following a collaboration between CNRS and Sanofi-Pasteur. He joined OM Pharma in 2008 (fully integrated within Vifor Pharma since 2009) as Head of Fermentation Unit and progressively took growing responsibilities in Industrial Operations. Since 2016, Julien is the Site Manager of Geneva Site leading around 200 people.

Beyond a solid Biotech Background, Julien is also Black Belt Certified and was in charge to deploy Operational Excellence on Geneva Site and beyond within Vifor Pharma over the last years.

Advisory board

Professor Offord taught and researched at the Universities of Cambridge and Oxford, U.K. from 1962-1980, collaborating with, among others, the Nobel Prize winners Frederick Sanger, César Milstein, Dorothy Hodgkin and Aaron Klug. In 1980 he became a Departmental Director at the Faculty of Medicine, University of Geneva, and later served as President of the School of Basic Medicine there. Robin became an Emeritus Professor in October 2005. He was a co-founder of the Swiss Institute for Bioinformatics. He served for ten years as a member of the Geneva government’s Council for Regional Economic Development. He is Chairman of the Board of Trustees of the Torrey Pines Institute for Molecular Studies (Port St Lucie, Florida and San Diego) and is the first non-US President of the American Peptide Society. Robin Offord shared the 2002 “Man of the Year, Switzerland” award of the Swiss financial newspaper L’agefi and in 2005 received the American Peptide Society’s Makineni Award. Mr. Offord serves as a board member and is Chairman of the Advisory Board of Eclosion.

Denis Hochstrasser is a practising internist and clinical chemist. He manages the clinical pathology department and the central clinical chemistry and biological examination laboratories at Geneva’s university hospitals, supervises the computational activities of the medicine faculty at Geneva University, and runs a leading international multidisciplinary research group in proteomics. Prof. Hochstrasser cofounded the Institut Suisse de Bioinformatique, GeneBio SA, and Geneprot Inc.

Karl-Heinz Krause is Professor of Medicine at the Faculty of Medicine & University Hospitals of Geneva, as well as honorary professor at the Bejing Hospital, China. He received his MD from the Ludwig-Maximilian University (Munich) in 1982. From 1982 to 1989, he received clinical training in internal medicine and infectious diseases at the Universities of Munich, Geneva and Iowa. Starting in 1984, Prof. Krause has been actively involved in inflammation research. Since 1998, he has focused his research further on mechanisms of aging and treatment of age-associated diseases, in particular on the NOX family of NADPH oxidases as a pathophysiologically important source of oxygen radicals. He is an elected member of the Swiss Academy of Medical Sciences and the American Society for Clinical Investigation

Jean-Yves Le Cotonnec obtained a bachelor’s degree in engineering, a doctorate in medicine and a master’s in statistics in Paris. For 14 years, he occupied senior positions in the pharmaceutical industry, including posts at Novartis and Serono. In 1995 he founded Triskel Integrated Services SA, a company that defines and implements strategies to develop and register medical products in Europe and the USA, working in strategic cooperation with traditional contract research and manufacturing organisations. He has been involved in the development and registration of over ten drugs, including several blockbusters.

Jean-Marc Leroux is the Chief Innovation Officer of Covance and General Manager CCLS Europe. He has been in this role since February 2014. Throughout his 15-year career with Covance, Jean-Marc has been instrumental in shaping the company’s Central Laboratory strategy and securing new talent and technology to deliver strategic advances in that business. He progressed through various leadership positions in Central Laboratories, including Vice President of Global Laboratory Operations and Scientific/ Technical Affairs, Vice President for all Central Laboratory Global Operations (Laboratory, Sample Management/Lab Pre-analytical Services, Investigator Site Support, Logistics, and Kit Production) and most recently Vice President of Global Innovation & GM Europe for CLS. He has always been dedicated to identifying new technology and business innovations throughout his career at Covance, advocating for state-of-the-art laboratory automation, advances in informatics and new services like biomarkers and point-of-care devices. Prior to joining Covance, Jean-Marc launched his own network of diagnostics labs in France, implemented the central laboratory division for clinical trials at Pasteur Institute and worked in different European CROs and served as a board member for Eclosion and Metaphora. Headed by Jean-Marc, Covance’s Geneva site has earned a string of awards for carpooling and reducing biohazard waste, including First Prize of Economy in 2014 from Geneva Chamber of Commerce.

Mr. Leroux holds doctorate degrees in pharmaceutics (Sc. Pharmaceutics) and pharmacy (PharmD); a National Diploma in biochemistry, hematology, bacteriology and immunology; and a University Diploma in biological and medical engineering. He is the first prize recipient of the Behring Award in Biology and “Ancien interne des Hopitaux”.

Frédéric Levy  and his team manage the Evaluation of innovative therapeutics at Debiopharm International SA in Lausanne, Switzerland. He obtained his doctoral degree in biochemistry at the Karolinska Institute in Stockholm, Sweden and spent several years as a postdoctoral fellow at the California Institute of Technology in Pasadena. He moved then to Switzerland to take a position at the Lausanne Branch of the Ludwig Institute for Cancer Research, where he successively awarded a Young Investigator Award of the Cancer Insitute, a Professorship of the Swiss National Funds, an Associate Membership of the Ludwig Institute and an Associate Professorship of the University of Lausanne. His area of expertise is drug development in oncology, immunology and infectious diseases. During his career, Frédéric was Vice President of the Swiss Society of Biochemistry, Board Member of the Platform Biology of the Swiss Academy of Science, jury member of the Friedrich Miescher Award and Board Member of the FEBS.

Andrew Parker has a Ph.D. from the National Institute for Medical Research (UK), carried out post-doctoral studies at Johns Hopkins School of Medicine (USA) and completed an MBA with Warwick Business School (UK). He has published more than 25 peer-reviewed scientific papers in renowned international journals. Andrew  has twenty years of experience in drug discovery and early clinical development within pharmaceutical and biotechnology sectors.  Actually, he is CSO at Zealand Pharma

Oern R. Stuge is director of Impulse Dynamics NV. He was first Vice President, a member of the operating committee member and president for Europe, Canada, Latin America and emerging markets at Medtronic Inc. His numerous life sciences projects in areas such as Rx, Dx, nutrition and medical devices have given significant experience and a reputation as a leading force in this domain. Oern was a member of Medtronic’s management team for 12 years, serving as president for cardiac surgery and president for Europe and Central Asia, where he was responsible for transforming the cardiac surgery business and accelerating the growth of Medtronic companies in Europe with cardiovascular, neurological and spinal franchises. Before joining Medtronic, Oern served first as CEO of Medinor A/S, a Norwegian medical technology company, and then for Abbott Laboratories, where he was regional director and managing director for the Netherlands and the Nordic countries. He is a principal adviser to HealthCap, a life sciences investment fund with $1.5 billion under management; a member of the supervisory board of Mediq BV, an international medicines and pharmaceuticals distributor; and a director of Nobel Biocare AG, a world leader in dental implants. Dr Stuge graduated in medicine at Oslo University, and gained an MBA from the IMD business school in Lausanne

Timothy Wells is the Chief Scientific Officer for MMV, Medicines for Malaria Venture. Before joining that organisation, he was senior executive Vice President of research for Serono, conducting clinical trials on a number of innovative molecules. From 1997 to 2007, he worked at Glaxo’s molecular biology institute in Geneva, where he managed research into protein biochemistry and chemotactic cytokines. An enzymologist by training, his research interests included the relationships between protein structure and function, and the role of cytokines in controlling host responses. He has contributed to over 180 scientific publications and several patent registrations. He gained a doctorate in chemistry from London’s Imperial College for his research into protein engineering under the supervision of Sir Alan Fersht, and then obtained an ScD from Cambridge University for his work on the cytokine biology. He is a member of the Royal Society of Chemistry.

Submit your project

SUBMIT YOUR PROJECT

Get in touch

CONTACT US
© 2016 Fondation Eclosion
All rights reserved
Webdesign: Comstone / Pierre Chassany
WordPress Development: Olivier Gisiger